Indiana is included in a settlement with Boehringer Ingelheim Pharmaceuticals Inc. The $13.5 million settlement involves alleged off-label marketing, as well as deceptive and misleading representations in prescription drug promotions. All 50 states and the District of Columbia were involved in the settlement.

The pharmaceuticals, Indiana Attorney General Curtis Hill's Office says, are: Micardis, Aggrenox, Atrovent and Combivent. BIPI's consent judgment includes limiting availability of product sampling, ending financial incentives for sales involving off-label use of the drugs, ensure information on the drugs is provided in an unbiased way and refer all off-label information requests to the company's medical division.

You can connect to more about the settlement by clicking here.